文献速递肿瘤 PET/CT神经核医学甲状腺核医学

靶向生长抑素受体与整合素αvβ3的双靶向单次扫描评估肺癌与神经内分泌肿瘤

Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin αvβ3.
PubMed 文献 · Clin Nucl Med · 2019-01-01

本试点研究纳入32例病理确诊肺癌(18例NSCLC、14例SCLC)和12例神经内分泌肿瘤(8例NET、4例NEC)患者,行Ga-NOTA-3P-TATE-RGD PET/CT,并与Ga-NOTA-TATE、Ga-NOTA-RGD或F-FDG PET/CT比较。结果显示双靶向探针在NSCLC、SCLC和NET中T/B比值显著更高,在NEC中与F-FDG无显著差异,初步证明单次扫描双靶向评估的可行性。

要点

  • 双靶向Ga-NOTA-3P-TATE-RGD PET/CT可在单次扫描中评估肺癌与神经内分泌肿瘤。
  • NSCLC中双靶向T/B比值显著高于Ga-NOTA-TATE(4.54±3.00 vs 4.10±2.83,P=0.0058)。
  • NET中双靶向T/B比值显著高于F-FDG(36.13±33.84 vs 2.91±1.71,P=0.0234)。

核心结论

  • 概念验证研究初步证明双靶向Ga-NOTA-3P-TATE-RGD PET/CT可在单次扫描中评估肺癌和神经内分泌肿瘤。

研究设计与样本

  • 试点研究纳入32例病理确诊肺癌患者(18例NSCLC、14例SCLC)和12例神经内分泌肿瘤患者(8例NET、4例NEC)。
  • 所有患者行Ga-NOTA-3P-TATE-RGD PET/CT,NSCLC患者另在3天内行Ga-NOTA-TATE PET/CT,SCLC患者行Ga-NOTA-RGD PET/CT,神经内分泌肿瘤患者行F-FDG PET/CT。
  • 测量原发肿瘤SUVmax与血池SUVmean并计算T/B比值进行比较。

主要发现

  • NSCLC中双靶向T/B比值显著高于Ga-NOTA-TATE(4.54±3.00 vs 4.10±2.83,P=0.0058)。
  • SCLC中双靶向T/B比值显著高于Ga-NOTA-RGD(6.06±6.09 vs 2.65±1.19,P=0.0344)。
  • NET中双靶向T/B比值为36.13±33.84,显著高于F-FDG的2.91±1.71(P=0.0234)。
  • NEC中双靶向T/B比值4.80±0.85与F-FDG的3.56±0.74无显著差异(P=0.1833)。

临床怎么用

  • 对于肺癌与神经内分泌肿瘤患者,可考虑使用双靶向Ga-NOTA-3P-TATE-RGD PET/CT单次扫描同时评估生长抑素受体2和整合素αvβ3表达。
  • 在NET评估中双靶向探针T/B比值显著高于F-FDG,提示其可能优于F-FDG用于NET显像。

局限性

  • 本研究为试点性概念验证研究,样本量有限。
  • NEC亚组例数少且双靶向与F-FDG的T/B比值无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This pilot study aimed to prove the complementary value of a novel Gallium-labeled heterodimeric peptide, Ga-NOTA-3P-TATE-RGD, in detection and evaluation of tumors with somatostatin receptor subtype 2 or integrin αvβ3 overexpression, including non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), neuroendocrine tumor (NET), and neuroendocrine carcinoma (NEC). METHODS: With institute review board approval and written informed consent, 32 patients with pathologically diagnosed lung cancer (18 NSCLC, 14 SCLC) and 12 patients with neuroendocrine neoplasm (8 NET, 4 NEC) patients were recruited to undergo Ga-NOTA-3P-TATE-RGD PET/CT. For comparison, the NSCLC patients also underwent Ga-NOTA-TATE PET/CT, the SCLC patients underwent Ga-NOTA-RGD PET/CT, and the neuroendocrine neoplasm patients underwent F-FDG PET/CT within 3 days. The maximum standardized uptake value (SUV) of the primary tumor (T) and mean SUV of the blood pool (B) were measured, and the T/B ratios were calculated for comparison. RESULTS: In the primary tumors of NSCLC, the T/B ratios of Ga-NOTA-3P-TATE-RGD were significantly higher than those of Ga-NOTA-TATE (4.54 ± 3.00 versus 4.10 ± 2.83, P = 0.0058). In SCLC, the T/B ratios of Ga-NOTA-3P-TATE-RGD were significantly higher than those of Ga-NOTA-RGD (6.06 ± 6.09 versus 2.65 ± 1.19, P = 0.0344). In NET, the T/B ratios of Ga-NOTA-3P-TATE-RGD were 36.13 ± 33.84, significantly higher than those of F-FDG (2.91 ± 1.71, P = 0.0234). In NEC, there were no significant difference between the T/B ratios of Ga-NOTA-3P-TATE-RGD (4.80 ± 0.85) and those of F-FDG (3.56 ± 0.74, P = 0.1833). CONCLUSIONS: This proof-of-concept study preliminarily demonstrates the efficacy of the dual targeting Ga-NOTA-3P-TATE-RGD PET/CT in the evaluation of lung cancer and neuroendocrine neoplasm in a single scan.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Wang H, Tan H, et al. Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin αvβ3. Clin Nucl Med. 2019. PMID: 31274560. doi:10.1097/RLU.0000000000002680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。